The investment comprises two organic solvent processing rooms, designed to provide Colorcon’s Latin American customers to capacity to “conduct studies using organic solvents in the preparation of finished dosage forms.”
And, while a range of formulation development technologies will be available, Colorcon highlighted the new labs capacity for modified-release drugs as a particular strength.
Dennis Cummings, president of Colorcon Americas, explained that the expansion is part of a wider South American growth programme, explaining that: “Colorcon plans continued capital investment in our facilities as well as increasing our services in the region.
“We feel privileged to assist in the development of the rapidly growing Latin American pharmaceutical market, and honored to help our customers meet their technical and financial targets."